In today’s briefing:
- InSilico Medicine (英矽智能) IPO: AI Assets as Upside
- Medline Returns to Public Markets in Landmark IPO Debut
- Shanghai Forest Cabin IPO: Delivers Essence-Tial Growth, Investors Can Put A Skin in The Game
- Hybridan Research: Physiomics plc
InSilico Medicine (英矽智能) IPO: AI Assets as Upside
- InSilico Medicine, an AI-driven drug discovery and development, launched its IPO to raise at least USD 293 million via a Hong Kong listing.
- In this note, we look at the deal terms and provide a valuation for the company.
- We think the valuation is anchored by its innovative assets while the AI asset value provides upside.
Medline Returns to Public Markets in Landmark IPO Debut
- December 17, 2025 — Medline Industries, Inc. (NASDAQ: MDLN) began trading today on the Nasdaq Global Select Market following the pricing of its initial public offering at $29.00 per share.
- Shares opened at $35.00 in their first public trade, representing an immediate gain of approximately 21 percent, and continued to build momentum throughout the session.
- By the close, the stock finished near $41.00, delivering a first-day increase of roughly forty percent and marking one of the most consequential IPO debuts of 2025.
Shanghai Forest Cabin IPO: Delivers Essence-Tial Growth, Investors Can Put A Skin in The Game
- Shanghai Forest Cabin launched its Hongkong IPO aiming to raise up to HK$1086.2M. The company plans to sell 13.97M shares at HK$77.77 per share.
- Shanghai Forest Cabin (SFC) are a premium domestic skincare brand in China with a focus on the anti-wrinkle and firming skincare market, under their flagship brand Forest Cabin.
- The company’s business model is robust. We think Shanghai Forest Cabin issue is attractively priced and investors can surely look to invest in this growth story.
Hybridan Research: Physiomics plc
- A flow of new contracts have been announced so far in December adding to the evidence of business progress.
- The relatively new biometrics department reported a new client, Global Antibiotic Research & Development Partnership (GARDP).
- This is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure sustainable access.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
